Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Seventy‐seven patients with a primary diagnosis of social phobia (DSM‐III‐R) were randomized to treatment with the reversible and selective monoamine oxidase type A inhibitor brofaromine (n= 37) or placebo (n= 40) for 12 weeks in a double‐blind trial. A fixed dose of 150 mg/day or a matching placebo was given after a 2‐week dose titration phase. Patients with additional diagnoses of simple phobia, generalized anxiety disorder, dysthymia or major depressive disorder currently in remission were accepted. Patients with other Axis I mental disorders were excluded. In the brofaromine group, 78% of the patients scored much or very much improved on the Clinical Global Impression scale compared with 23% in the placebo group. The anxiety and avoidance scores on the Liebowitz Social Anxiety Scale (LSAS) were significantly reduced in favor of brofaromine. The clinical effects were not significantly correlated with the plasma concentration of brofaromine. After 12 weeks the brofaromine group scored significantly Jower than the placebo group on a core depression part of the Montgomery‐Åsberg Depressid Rating Scale. After 12 weeks of treatment the brofaromine group had significantly higher total scores on the LSAS than an age‐ and gender‐matched group of healthy controls. The brofaromine group improved further during 9‐month follow‐up treatment period, whereas 60% of the placebo responders who continued long‐term treatment relapsed. The most common side effects in the brofaromine group were sleep disturbances, dry mouth and nausea.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“A substantial comorbidity has, however, been found with, for instance, major depressive (9-1 l), dysthymic (12, 13), generalized anxiety (14, 15), and panic (16-18) disorders.”
BackgroundPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Cited by
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Stein, M. B., Fyer, A. J., Davidson, J. R. T., Pollack, M. H., & Wiita, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.756 · Cited by 262
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Metadata
- Authors
- Fahlén, T., Nilsson, H. L., Borg, K., Humble, M., & Pauli, U.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 1995-11
- Volume
- 92
- Issue
- 5
- Pages
- 351-358
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W1999498090
- Cited by
- 104
- References
- 3
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1600-0447.1995.tb09596.x
- The paper
- Fahlén, T., Nilsson, H. L., Borg, K., Humble, M., & Pauli, U. (1995). Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1995.tb09596.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.